Sensorion SAS (FR:ALSEN)
:ALSEN
ALSEN Stock Chart & Stats
€0.36
€0.00(0.00%)
At close: 4:00 PM EST
€0.36
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.15 - €0.81
Previous CloseN/A
Volume61.80K
Average Volume (3M)540.27K
Market Cap
€183.25M
Enterprise Value€89.50M
Total Cash (Recent Filing)€47.46M
Total Debt (Recent Filing)€1.23M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Sep 23, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding514,946,960
10 Day Avg. Volume740,129
30 Day Avg. Volume540,266
Financial Highlights & Ratios
PEG Ratio-0.49
Price to Book (P/B)2.28
Price to Sales (P/S)0.00
P/FCF Ratio-3.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.00Price Target Upside177.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.04
Revenue Forecast (FY)€18.91M
Bulls Say, Bears Say
Bulls Say
Financing And Partnership ValidationStrategic equity investment from a major pharmaceutical company and recent financing extend the cash runway and provide external validation, enabling planned clinical readouts and regulatory filings to proceed.
Regulatory AdvancementPlanned clinical trial application for the GJB2 gene therapy positions the program as a potential first-to-market treatment for common congenital and early-onset hearing loss, offering a large addressable patient population.
Safety ProfileSurgical and intra-cochlear administration of SENS-501 was well tolerated with no serious adverse events, supporting a favorable safety profile that may ease regulatory review for the program.
Bears Say
Competitive RiskRival programs that reach approval first would force the company to demonstrate a clearly superior clinical outcome to secure market share, heightening commercial and investment risk.
Dose Escalation RiskMove to a higher dose for SENS-501 and initiation of regulatory discussions suggest the initial dose may be insufficient, increasing the likelihood of extended development timelines.
Efficacy UncertaintyAbsence of specific efficacy metrics increases uncertainty about the magnitude of clinical benefit and raises the risk that observed responses may be underwhelming.
Sensorion SAS News
ALSEN FAQ
What was Sensorion SAS’s price range in the past 12 months?
Sensorion SAS lowest stock price was €0.15 and its highest was €0.81 in the past 12 months.
What is Sensorion SAS’s market cap?
Sensorion SAS’s market cap is €183.25M.
When is Sensorion SAS’s upcoming earnings report date?
Sensorion SAS’s upcoming earnings report date is Sep 23, 2026 which is in 178 days.
How were Sensorion SAS’s earnings last quarter?
Sensorion SAS released its earnings results on Mar 18, 2026. The company reported -€0.04 earnings per share for the quarter, beating the consensus estimate of -€0.06 by €0.02.
Is Sensorion SAS overvalued?
According to Wall Street analysts Sensorion SAS’s price is currently Undervalued.
Does Sensorion SAS pay dividends?
Sensorion SAS does not currently pay dividends.
What is Sensorion SAS’s EPS estimate?
Sensorion SAS’s EPS estimate is -0.04.
How many shares outstanding does Sensorion SAS have?
Sensorion SAS has 514,946,960 shares outstanding.
What happened to Sensorion SAS’s price movement after its last earnings report?
Sensorion SAS reported an EPS of -€0.04 in its last earnings report, beating expectations of -€0.06. Following the earnings report the stock price went down -12.651%.
Which hedge fund is a major shareholder of Sensorion SAS?
Currently, no hedge funds are holding shares in FR:ALSEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sensorion SAS
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
ALSEN Stock 12 Month Forecast
Average Price Target
€1.00
▲(177.78% Upside)
Technical Analysis
Innate Pharma SA
―
Nanobiotix
―
Transgene
―
OSE Immunotherapeutics SA
―
MaaT Pharma
―
Options Prices
Currently, No data available
---